UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities ~~and~~ Exchange Act of 1934

Date of Report (~~date~~Date of earliest event reported): August 3 10, 2023

Tengjun Biotechnology Corp.

(Exact ~~name~~ Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Nevada	333-169397	27-3042462
(State or other jurisdiction	(Commission File Number)	(~~I.R.S.~~IRS Employer
of incorporation)		Identification ~~Number~~No.)

East Jinze Road and South Huimin Road, Food Industry Economic and Technology Development District, Jinxiang County, Jining City, Shandong Province, China N/A (Address of principal executive offices) (Zip Code)

~~Jinxiang~~Registrant’s ~~County~~telephone number, ~~Jining~~including ~~City, Shandong~~area ~~Province,~~code: ~~China~~(86) 0537-8711599

(Address of principal executive offices and zip code)

(86) 0537-8711599

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐Indicate by ~~Soliciting~~check ~~material~~mark ~~pursuant~~whether tothe registrant is an emerging growth company as defined in Rule ~~14a~~405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-122 ~~under~~of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14a~~12b-122 of this chapter).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Trading Symbol(s) Name of each exchange on which registered: None None None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~Securities registered ~~5.02~~pursuant ~~Departure~~to ofSection ~~Directors~~12(b) ~~or Certain Officers; Election~~ of ~~Directors;~~the ~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Act:

~~Tengjun~~Title ~~Biotechnology~~of ~~Corp. wishes to~~each ~~announce~~class ~~that~~Trading ~~Mr.~~Symbol(s) ~~Xianchang~~Name ~~Ma, the Chief Executive Officer, Chief Financial Officer and Director~~ of ~~the~~each ~~Company,~~exchange ~~passed away~~ on ~~August 3,~~which ~~2023.~~registered ~~Mr.~~N/A MaN/A served on the Board of the Company since December 2019. The Company and its management have extended their condolences to the family of the late Mr. Ma and will update stockholders of further developments in this regard.N/A

1Item 4.02 Non-reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

~~SIGNATURES~~On August 10, 2023, the Company’s Board of Directors (the “Board”) concluded that the Company’s previously issued financial statements, contained within its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.

~~Pursuant to the requirements~~Item of5.02 ~~the~~Departure ~~Securities Exchange Act~~ of ~~1934,~~Directors asor ~~amended,~~Certain ~~the~~Officers; ~~Registrant~~Election ~~has~~of ~~duly~~Directors; ~~caused~~Appointment ~~this~~of ~~report~~Certain toOfficers; beCompensatory ~~signed~~Arrangements ~~on its behalf by the undersigned~~of ~~hereunder~~Certain ~~duly authorized.~~Officers

Date: August 7, 2023
	Tengjun Biotechnology Corp.
	By:	/s/ Huaping Lu
		Huaping Lu
		Director

On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company, until the next annual meeting of the Corporation’s shareholders, and until her successor is elected and qualified or until her prior disqualification.

2Ms. Qu, aged 48, graduated from Heilongjiang Agricultural Reclamation Teachers College in the PRC and is the legal representative of Jinxiang County Kanglong Water Purification Equipment Co., Ltd. since 2015. Ms. Qu is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Ms. Qu and any other persons pursuant to which she was appointed as Director, CEO and CFO of the Company. Ms. Qu is the late wife of Mr. Xianchang Ma, our previous Director, CEO and CFO, who passed away on August 3, 2023.

Item 9.01 Exhibits

104	Inline XBRL

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively, the “Filings”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant’s management as well as estimates and assumptions made by Registrant’s management. When used in the Filings the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to Registrant or Registrant’s management identify forward-looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrants ability to complete the restatement and correction of the accounting errors described in this Current Report on Form 8-K, the Registrant’s industry, and the Registrant’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 14, 2023

	Tengjun Biotechnology Corp.

	By:	/s/ Huaping Lu
	Name:	Huaping Lu
	Title:	Director

Filing Compare · Tengjun Biotechnology Corp.